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Dissertation Abstract 
Anti-neutrophil cytoplasmic antibody (ANCA) testing at Groote Schuur 
Hospital: Adherence to indications for testing 
Ramona Govender1, Bridget Hodkinson2 
1 Department of Internal Medicine, Groote Schuur Hospital, Cape Town, South 
Africa 
2 Division of Rheumatology, Groote Schuur Hospital, Cape Town, South Africa 
Introduction: Appropriate use of laboratory investigations is increasingly important 
in resource-constrained environments. We reviewed the anti-neutrophil cytoplasmic 
antibody (ANCA) testing practices in a tertiary hospital in South Africa. 
Methods: We conducted a retrospective file review of all ANCA tests ordered 
through the National Health Laboratory Services (NHLS) at Groote Schuur Hospital 
over 12 months (01/01/17 – 31/12/17), including both inpatient and outpatients, and 
extracted sociodemographic and clinical details. All requests were assessed against 
the International Consensus Statement of 1999 which provides clinical guidelines for 
the indications for ANCA testing.  
Results: Of the 945 ANCA tests requested, 790 patient records were reviewed, 62 
patients had multiple tests and 155 patient records were missing. Most tests (63.5%) 
were performed on inpatients. Only 193 patients (24.4%) had indications for ANCA 
 5 
testing meeting guidelines. The commonest non-guideline indications were critical 
limb ischemia (9.6%), stroke (7.3%), uveitis (5.7%), renal impairment (4.9%) and 
interstitial lung disease (4.4%). The departments for requesting ANCA tests most 
commonly were Medicine, Ophthalmology, Neurology and Surgery, with Surgery 
having 99% of its tests for non-guideline indications. Ten patients (1.3%) were 
diagnosed with ANCA-associated vasculitis (AAV), and of these 9 had renal-limited 
vasculitis. These patients were predominantly female (70.0%) with mean (SD) age of 
54.5 (16.4) years. Twenty-six patients tested ANCA positive without any evidence of 
AAV. Of these false positives, ten (38.4%) were human immunodeficiency virus 
(HIV) positive, three (11.5%) had tuberculosis (TB), and three (11.5%) had other 
autoimmune diseases. The total estimated cost of ANCA tests for the year was 
ZAR274 046, with ZAR17 490 spent on duplicate testing and ZAR208 275 spent on 
non-indicated clinical conditions. 
 
Conclusion: ANCA testing occurred outside standard guidelines in three-quarters of 
requests, and duplicate testing was common, with large cost implications. Chronic 
infections HIV and TB, and autoimmune conditions accounted for half of the false 
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Chapter 1: Introduction and Literature Review 
Context: 
The rising cost of laboratory investigations and equitable distribution of health care 
resources have become important issues world-wide, with socio-political 
implications, particularly in resource constrained environments. However, health care 
workers often lack insight into the costs of tests and treatment, and frequently order 
tests without a deep understanding of the test’s clinical utility. In any population, 
ANCA-associated vasculitis (AAV) is a rare multi-system condition that requires a 
high index of suspicion and testing within an appropriate clinical framework. This 
audit was undertaken to investigate the number of anti-neutrophil cytoplasmic 
antibody (ANCA) tests ordered over 12 months and review the adherence to 
international guidelines for these tests. 
Background: 
Anti-neutrophilic cytoplasmic antibody tests 
Anti-neutrophil cytoplasmic antibody (ANCA) tests were first described in 1982 and are 
now integral to our understanding and classification of small vessel vasculitis [1]. The 
revised nomenclature in the 2012 Chapel Hill Consensus Conference (CHCC 2012) 
added a new category of vasculitis, the ANCA-associated vasculitis (AAV) which was 
defined as a necrotizing small vessel vasculitis with few or no immune deposits. The 
major clinicopathologic variants are granulomatosis with polyangiitis (GPA, 
previously known as Wegener’s granulomatosis), microscopic polyangiitis (MPA) and 
eosinophilic granulomatosis with polyangiitis (EGPA, previously known as Churg-
Strauss syndrome), and its localized forms (pauci-immune necrotizing and 
cresenteric glomerulonephritis [GN]) [2] (Table 1). 
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Anti-neutrophilic cytoplasmic antibodies are autoantibodies directed against antigens 
found in the cytoplasmic granules of neutrophils and monocytes [3]. Two types of 
ANCA patterns are identified in small vessel vasculitis using indirect 
immunofluorescence (IIF): cytoplasmic ANCA (c-ANCA) directed against proteinase 
3 (PR3), and peri-nuclear ANCA (p-ANCA) targeting myeloperoxidase (MPO) [4]. In 
recognition of the important role of ANCA serology in these diseases, CHCC 2012 
called for adding a prefix to the clinicopathologic phenotype indicating ANCA 
specificity as either MPO-ANCA or PR3-ANCA or ANCA negative [2]. These auto-
antigens have different genetics and correlate better with different human leukocyte 
antigen (HLA) risk genes than its clinicopathological variants [5]. 
 
The manifestations, clinical course and relapse rates of AAV correlate closely with 
target antigen [6] [7]. Ear, nose, eye and lung involvement appear to occur more in 
patients with c-ANCA/ PR3 positivity, with renal manifestation to a lesser degree. 
This group also tends to have more relapses with a poorer outcome and higher 
mortality [8, 9]. c-ANCA occur in 95% of cases of new onset GPA and 40% of EGPA 
[4]. In comparison, the p-ANCA/ MPO group display more renal involvement, 
typically a pauci-immune segmental necrotizing GN, which could occur alone or with 
systemic features, and fewer relapses [10]. Positive p-ANCA are seen in in 80% of 
new onset MPA [4]. The target antigen has also been shown to have histological 
implications on the type of GN found at renal biopsy.  Anti-PR3-AAV is associated 
with more granulomatous inflammation and necrosis while anti-MPO-AAV has a 
lesser degree of inflammation and more sclerosis [11].  
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With time and a wide variety of ANCA testing in formalin and ethanol fixed 
neutrophils, other patterns of ANCA have been identified including nuclear ANCA, 
atypical ANCA and double-positive p-ANCA and c-ANCA, making the need for more 
specific ANCA assays and guidelines for testing vital  [12]. The international 
consensus statement guidelines (1999) showed that the combination of IIF and 
ELISA tests offered good clinical utility [13, 14]. Ten percent of ANCAs were 
detectable by IIF while remaining negative by first-generation ELISAs, while in 5% of 
AAV cases only the ELISA was positive with negative IIF [14]. This discrepancy 
highlighted the need for combination testing or an ELISA test if AAV was highly 
suspected despite a negative screening IIF. The combined use of IIF and first-
generation ANCA ELISAs resulted in an increase in the diagnostic performance from 
a specificity of 76% to 98% respectively [14]. However, despite this recommendation, 
the concern in the clinical setting was over the delay in diagnosis and increased 
costs of these tests.  
 
In 2017, Bossuyt and colleagues discussed the newer and more improved 
technologies for ANCA testing; with second and third generation ELISAs including  
direct and capture ELISAs, as well as new fluorescent-enzyme immuno-
assays(FEIA), for PR3- and MPO-ANCA detection. These tests were again shown 
outperforming the classic IIF. They proposed a new strategy for using ELISA as a 
first line screening in patients suspected with AAV from the 1999 guideline 
scenarios. A follow up second assay, like IIF, could be used to increase sensitivity if 
ELISA was negative. They also opened the floor to using newer confirmatory 
immunoassays as long as they were internally validated [15]. Again, clinicians were 
told not to forget that the gold standard for diagnosis of AAV still remained biopsy of 
 12 
the affected organ in the setting of a high clinical suspicion and negative 
immunoassay testing. This integral point had been highlighted previously by 
Damoiseaux et al in 2005 who demonstrated 10 out of 87 patients who were capture 
ELISA negative despite being confirmed with AAV by suggestive renal histology with 
a pauci-immune necrotising GN [16].   
 
False positive anti-neutrophil cytoplasmic antibody tests 
A positive ANCA test is not a definitive diagnostic indicator of AAV with its presence 
found in non-vasculitic diseases. While in 2002, Mandl et al demonstrated a false 
positive rate around 2.2%, mainly p-ANCA and anti-MPO antibodies [17]. More 
recent audits in Greece [18], Netherlands [19], India [20] and Canada [21] reported 
higher rates of 80%, 50%, 85% and 71% respectively. Non-vasculitic diseases 
include inflammatory bowel disease (up to 70% ANCA positivity in ulcerative colitis, 
30% in Crohns disease), primary sclerosing cholangitis (90%), chronic autoimmune 
hepatitis (70%), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) 
(20%) [3]. Edgar and McMillan showed that 18.2% ANCA positivity was due to RA 
and that 27.9% in itself accounted for the connective tissue disorders as a whole, 
making it another source of false positives [22].  
 
False-positive ANCA tests have also been documented in the setting of chronic 
infection such as tuberculosis (TB), leprosy, suppurative lung disease [23], and 
amoebic liver abscess[24]. Among 60 West Africans, 6.7% of patients with TB and 
malaria were found to be ANCA positive by IIF and demonstrated positive IgM 
antibodies to MPO [25]. In cases of infective endocarditis, patients may present with 
multi-system disturbances resembling an autoimmune process, with a positive ANCA 
 13 
and making diagnosis even more uncertain and less straightforward. This is 
important as distinguishing an infective from an autoimmune process is needed to 
guide appropriate therapy [25]. There has also been an association of recurrent 
infections with dual anti-PR3 and anti-MPO positivity, with no indication of any 
particular pattern of clinical outcome [26].  
 
Anecdotal reports of associations between ANCA antibodies and viral infections 
including HIV, hepatitis B and C, have been noted [27]. HIV infection may evoke 
ANCA in 20 to 83% of cases, mainly positive by IIF and a small percentage by 
ELISA [27] [28]. Cornely et al found anti-MPO positivity in only one out of 199 HIV 
patients (0.5%) [29], whereas Koderisch et al found a faint c-ANCA positivity in 24 
out of 29 (83%) HIV-infected patients [30]. Although many of these studies have 
been performed in a pre-highly active antiretroviral therapy (HAART) era, Iordache 
and colleagues showed the persistence of autoantibodies in active HIV despite good 
virologic control. They demonstrated that 45% had at least one autoantibody 
present, especially antinuclear antibodies (ANA) (33%) and ANCA (13%), without 
clinically relevant disease [31].  
 
However, with the advent of effective HAART and good viral and immunological 
control, there has been a higher emergence of autoimmune diseases in these 
patients with reconstituted immune systems [32]. Vasculitis associated with HIV has 
been reported in all stages of HIV infection [33]. ANCA shows a high sensitivity and 
specificity for systemic necrotizing vasculitis and pauci-immune cresenteric 
glomerulonephritis in patients with HIV [34]. In addition to infections, certain 
medications like anti-thyroid drugs, levamisole-adulterated cocaine, minocycline and 
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hydralazine may induce ANCA and associated small-vessel vasculitis. 
Propylthiouracil has also been linked as a common cause of drug induced ANCA 
positive vasculitis, expressing high levels of MPO ANCA [3, 23].  
 
Indications for anti-neutrophil cytoplasmic antibody-associated vasculitis testing 
Because of the high false positive rate for indiscriminate ANCA testing, the 
international consensus statement of 1999 provided clinical guidelines of indications 
for ANCA testing [14] (Table 2). The aim of these guidelines is to increase the 
positive predictive value (PPV) of ANCA testing by limiting the test to patients with 
clinical features suggestive of AAV [14] . It was demonstrated that ANCA exhibit a 
PPV of 54% and negative predictive value (NPV) of 99% in conventional clinical 
settings. Variabilities also existed across tests due to the prevalence of AAV in the 
population examined, implying that better predictive values could be seen in groups 
of patients with higher pretest probability [17]. Encouragingly, studies show that AAV 
is seldom missed when testing is restricted to indications meeting the 1999 clinical 
guidelines [14]. Mandl et al calculated a potential 27% decrease in false positive 
rates if strict adherence to the guidelines were maintained. Unfortunately, clinicians 
do not always adhere to these guidelines, with 35-65% of tests being requested 
without indication [20, 35]. Clinical audits from differing counties and populations are 
summarized in Table 3. 
 
Anti-neutrophil cytoplasmic antibody titres 
There are also fluctuations in ANCA titres with higher titres usually occurring at 
presentation and decreasing with treatment initiation and stabilization of disease. 
Rebound increase in titres were seen in about half of GPA patients with disease 
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relapse [16, 36]. Currently, we do not know the clinical significance of change in 
titres in predicting AAV relapse, nor which test best defines these relapses. It was 
noted in a meta-analysis study that a rise in ANCA titers or persistence of ANCA 
during remission of AAV only mildly predicts the risk of relapse, hence serial ANCA 
testing is not recommended at this stage [37].   
 
Epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis testing 
The pre-test probability of ANCA testing is also dependent on the epidemiology of 
AAV within the testing region. A higher prevalence will of course beget a higher 
predictive value. Anti-neutrophil cytoplasmic antibody-associated vasculitis is very 
uncommon, with a prevalence rate in Europe of 20 per million [38]. There is little 
information on the worldwide epidemiology and clinical features of these diseases. 
There are regional and ethnic differences in the clinical features of patients with 
AAV, with most of the information coming from the western caucasian populations 
[38]. In southern Europe, MPA is more common, compared to northern Europe 
where GPA is more frequently encountered. In Japan, MPA was the predominant 
subtype (83%), while GPA was more frequent in the United Kingdom (UK) (66%). In 
terms of the ANCA pattern, >80% of Japanese patients were p-ANCA/ anti-MPO 
positive, whereas two-thirds of UK patients were c-ANCA/ anti-PR3 positive. Renal 
involvement in MPA was very common in both countries but was much less common 
in GPA in Japan compared with the UK [39]. The ANCA subtype may play a role in 
epidemiology with PR3-ANCA vasculitis more common in northern Europe, northern 
north America and Australia while MPO-ANCA vasculitis found more in southern 
Europe, southern United States and Asia [40].  
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There appears to be a low prevalence of AAV in African populations, with few 
published papers on ANCA. Adebajo et al reported a seroprevalence of 7% for ANA 
and 30.3% for anti-cardiolipin antibodies amongst healthy west Africans, however no 
ANCA antibodies were found in this group [25]. This low incidence may be due to a 
low index of suspicion for these conditions, a lack of appropriate laboratory facilities 
and relevant medical personnel, resulting in little ANCA testing, or may reflect a true 
low prevalence amongst black African patients [38][37]. There is inadequate 
documentation of epidemiology of AAV in the developing world, but there are 
increasing reports indicating that these conditions are seen in Africa [38].  
 
Anti-neutrophil cytoplasmic antibody testing at Groote Schuur Hospital 
The National Health Laboratory Service (NHLS) testing of ANCA in Groote Schuur 
Hospital (GSH) consists of a fluorescence ELISA designed as a sandwich 
immunoassay that uses the EliA IgG method on the instrument Phadia 250 [41]. This 
is an in-vitro qualitative measurement of IgG antibodies directed against PR3 and 
MPO in human serum [41]. The NHLS state price list as effective from 1st April 2017 
is ZAR240.38 for both tests.  
 
Conclusion: 
This audit, evaluating the number of ANCA tests ordered, the inappropriateness of 
each test and the total cost of ANCA testing over 12 months at GSH, will allow better 
understanding of the negative, positive and false positive ANCA tests. It may 
demonstrate the need for gatekeeping of the test to strict ordering guidelines with the 
aim to decrease hospital costs as well as avoid inappropriate specialist clinic 
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referrals. In addition, the spectrum of AAV in patients attending a tertiary western 





Table 1: 2012 Revised International Chapel Hill Consensus Conference 
Nomenclature of Vasculitis2 
 
Large Vessel Vasculitis (LVV) 
Takayasu arteritis  
Giant cell arteritis 
Medium vessel vasculitis 
Polyarteritis nodosa (PAN) 
Kawasaki disease 
Small Vessel Vasculitis 
Antineutrophil cytoplasmic antibody associated vasculitis (AAV) 
Microscopic polyangiitis (MPA) 
Granulomatous with polyangiitis (Wegener’s)(GPA) 
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) 
Immune complex SVV 
Anti-glomerular basement membrane (anti-GBM) disease 
Cryoglobulinaemic vasculitis (CV) 
IgA vasculitis (Henoch-Schonlein) (IgAV) 
Hypo-complement urticarial vasculitis (HUV) (anti-C1q vasculitis)  
Variable vessel vasculitis (VVV) 
Bechet’s disease 
Cogan’s syndrome 
Single-organ vasculitis (SOV) 
Cutaneous leukocytoclastic angiitis 
Primary central nervous system 
Isolated aortitis 
others 





Vasculitis associated with probable aetiology 
Hepatitis C virus-associated cryoglobulinaemic vasculitis 
Hepatitis B virus-associated vasculitis 
Syphilis-associated aortitis 
Drug associated immune complex vasculitis 








Table 2: Clinical indications for anti-neutrophil cytoplasmic antibody testing*14 
 
Glomerulonephritis especially rapidly progressive GN 
Pulmonary haemorrhage especially pulmonary renal syndrome 
Cutaneous vasculitis with systemic features 
Multiple lung nodules 
Chronic destructive disease of the upper airways 
Long-standing sinusitis or otitis 
Subglottic tracheal stenosis 
Mononeuritis multiplex or other peripheral neuropathies 
Retro-orbital mass 
Scleritis 





Table 3: Summary of anti-neutrophil cytoplasmic antibody clinical audits 
worldwide 
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Introduction: Appropriate use of laboratory investigations is increasingly important in 
resource-constrained environments. We reviewed the anti-neutrophil cytoplasmic antibody 
(ANCA) testing practices in a tertiary hospital in South Africa. 
 
Methods: We conducted a retrospective file review of all ANCA tests ordered through the 
National Health Laboratory Services (NHLS) at Groote Schuur Hospital over 12 months 
(01/01/17 – 31/12/17), including both inpatient and outpatients, and extracted 
sociodemographic and clinical details. All requests were assessed against the International 
Consensus Statement of 1999 which provides clinical guidelines for the indications for 
ANCA testing.  
 
Results: Of the 945 ANCA tests requested, 790 patient records were reviewed, 62 patients 
had multiple tests and 155 patient records were missing. Most tests (63.5%) were performed 
on inpatients. Only 193 patients (24.4%) had indications for ANCA testing meeting 
guidelines. The commonest non-guideline indications were critical limb ischemia (9.6%), 
stroke (7.3%), uveitis (5.7%), renal impairment (4.9%) and interstitial lung disease (4.4%). 
The departments for requesting ANCA tests most commonly were Medicine, 
Ophthalmology, Neurology and Surgery, with Surgery having 99% of its tests for non-
guideline indications. Ten patients (1.3%) were diagnosed with ANCA-associated vasculitis 
(AAV), and of these 9 had renal-limited vasculitis. These patients were predominantly female 
(70.0%) with mean (SD) age of 54.5 (16.4) years. Twenty-six patients tested ANCA positive 
without any evidence of AAV. Of these false positives, ten (38.4%) were human 
immunodeficiency virus (HIV) positive, three (11.5%) had tuberculosis (TB), and three 
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(11.5%) had other autoimmune diseases. The total estimated cost of ANCA tests for the year 
was ZAR274 046, with ZAR17 490 spent on duplicate testing and ZAR208 275 spent on 
non-indicated clinical conditions. 
 
Conclusion: ANCA testing occurred outside standard guidelines in three-quarters of 
requests, and duplicate testing was common, with large cost implications. Chronic infections 
HIV and TB, and autoimmune conditions accounted for half of the false positive tests. We 




















Anti-neutrophil cytoplasmic antibodies (ANCA) are integral to the understanding and 
classification of small vessel vasculitis, and are important diagnostic tools for the ANCA-
associated vasculitis (AAV), a group of necrotizing small vessel vasculitis with few or no 
immune deposits.[1] Because of the high false positive rate for indiscriminate ANCA testing, 
the International Consensus Statement of 1999 provided clinical guidelines of indications for 
ANCA testing (Table 1).[2] The aim of these guidelines is to increase the positive predictive 
value (PPV) of ANCA testing by limiting the test to patients with clinical features suggestive 
of AAV. It has been shown that ANCA tests have a PPV of 54% and negative predictive 
value (NPV) of 99% in conventional clinical settings but with a PPV increase to 62% with 
application of guidelines.[3] Encouragingly, studies show that AAV is seldom missed when 
testing is restricted to indications listed in the 1999 clinical guidelines.[3] 
 
In African populations, AAV seems to be rare, with few published papers on ANCA 
antibodies. A combination of a low index of suspicion of AAV and a lack of appropriate 
laboratory facilities are likely explanations.[4] Amongst 60 west Africans, 6.7% patients with 
chronic infections (tuberculosis and malaria) were found to be anti-myeloperoxidase (MPO) 
ANCA positive, but no ANCA antibodies were found amongst healthy Africans.[5] 
 
The rising cost of laboratory investigations, and equitable distribution of health care 
resources have become important issues world-wide, with both social and political 
implications. In South Africa (SA), cost-effectiveness is a major criterion in developing 
clinical policies. We undertook an audit of all ANCA tests ordered in a tertiary academic 
hospital to determine adherence to indications for testing, the diagnostic accuracy of the test 
and to review the positive ANCA tests, with the aim of decreasing hospital costs as well as 
 31 
avoiding inappropriate specialist referrals. The University of Cape Town Faculty of Health 
Sciences Human Research Ethics Committee approved the study (HREC reference number 
443/2018). 
 
Patients and Methods 
A retrospective folder review of all ANCA tests ordered through the National Health 
Laboratory Services (NHLS) was conducted at a state-sector tertiary hospital  over 12 months 
(1/1/2017 – 31/12/2017). Case records were reviewed, and clinico-demographic features, 
requesting speciality, and comorbidities were collated. The indication for each ANCA test 
was assessed against the International Consensus Statement of 1999.  
 
The NHLS testing of ANCA was a fluorescence enzyme-linked immunosorbent assay 
(ELISA) sandwich immunoassay that uses the EliA IgG method on the instrument Phadia 




Descriptive statistics and normally distributed variables are presented as means with standard 
deviations, and sensitivity, specificity, PPV and NPV were calculated.  Analysis was done 
using IBM SPSS Statistics V26.  
 
Results 
Of 945 ANCA tests performed, 790 clinical records were found and reviewed, and 155 
patient records were missing (Fig. 1).  Sixty-two patients had multiple tests with a total of 
133 tests ordered. Most tests were ordered for inpatients 498 (63.0%) with 36.5% ordered for 
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outpatients, and 4 patients (0.5%) having tests from both. Overall, 193 (24.4%) patients had 
indications which met the 1999 guidelines for ANCA testing. The remaining 597 (75.6%) fell 
outside the guidelines.  
 
The major requesting departments were Medicine, Ophthalmology, Neurology and Surgery, 
with Surgery having 99% of its tests for non-guideline indications (Table 2). The commonest 
non-guideline indications were critical limb ischemia (9.6%), stroke (7.3%), uveitis (5.7%), 
acute kidney injury (4.9%) and interstitial lung disease (4.4%). The most common guideline 
indications were glomerulonephritis (GN) (52.1%), peripheral neuropathy (19.0%), scleritis 
(10.5%) and cutaneous vasculitis (9.0%).  
 
Ten patients (1.3%) were diagnosed with AAV over the 12 months, and these patients were 
predominantly female, of a mixed racial ancestry with a mean (SD) age of 54.5 (16.4) years 
(Table 3). One patient was diagnosed with ANCA-negative granulomatosis with polyangiitis 
(GPA), and 9 had renal-limited vasculitis (RLV) with pauci-immune necrotizing GN on renal 
biopsy and no extra-renal manifestations. Only five of the RLV patients were ANCA positive 
(most commonly MPO positive).  
 
Of all ANCA tests performed, 31 (3.9%) patients had positive ANCA tests, of which 5 were 
true positive tests, and 26 were false postives showing no evidence of AAV. Of these false 
positives, 11 (42.3%) were associated with chronic infections: human immunodeficiency 
virus (HIV), tuberculosis (TB), and syphilis, while three (11.5%) had autoimmune diseases 
(Table 4). No explanation for the positive results were found in 13 patients (50%). The 
sensitivity, specificity, PPV and NPV for the total cohort were 50.0%, 96.7%, 16.1% and 
99.3% respectively. 
 33 
 Of the 193 ANCA tests which met guideline indications for testing, there were 14 patients 
with positive ANCA tests, of which 5 were true positive tests, and 9 false positives showing 
no evidence of AAV. When only patients meeting guideline indications for testing were 
considered, the PPV improved but remained lower than described elsewhere, due to the high 
number of false positive tests seen in our setting: the sensitivity, specificity, PPV and NPV 
were 50.0%,  95.1%, 35.7% and 97.2% respectively.  The total estimated cost of ANCA tests 
for the year was ZAR 274 046, with ZAR 17 490 spent on duplicate testing and ZAR 208 275 
spent on non-indicated clinical conditions. 
 
Discussion 
Due to its multi-system heterogenous presentation, insidious onset, and rarity, small vessel 
vasculitis represents a diagnostic challenge and the ANCA test is an important screening tool. 
Our study demonstrates that only a quarter of ANCA tests had indications meeting the 1999 
international consensus statement guidelines, and this indiscriminate use of ANCA testing is 
costly, and lowers the test sensitivity and PPV. Elsewhere, similar studies have shown 33.4% 
and 50.0% of tests were within guideline indications. [7, 8] Gating policies to restrict ANCA 
testing have proven benefit, reducing false positive rates up to 27.0% [3] and increasing 
ANCA positivity by 11.8% [9] without missing AAV cases.  
 
False positive ANCA tests are well described, and in the present study resulted in a lower 
PPV than described elsewhere. [8, 10-12] In our study, there were 26 patients with positive 
ANCA test and no evidence of AAV, but chronic infection was noted in 42.3%. Elsewhere, 
chronic infection including TB, malaria, leprosy, suppurative lung disease, infective 
endocarditis, hepatitis B and C, and HIV have been noted to cause positive ANCA results. [5, 
13] In the pre-highly active antiretroviral therapy (HAART) era, Koderisch et al described c-
ANCA positivity in 24 out of 29 HIV-infected patients (83.0%).[14] More recently, in HIV 
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patients with mostly good viral control on HAART, 45.0% had at least one autoantibody 
present, especially ANA (33.0%) and ANCA (13.0%), without clinically relevant disease.[15] 
 
In the present study, 11.5% of the false positive ANCA tests were seen in patients with 
autoimmune diseases, and this is described elsewhere, particularly amongst patients with 
chronic autoimmune hepatitis (70.0%), rheumatoid arthritis and systemic lupus 
erythematosus (20.0%).[16] Other causes of positive results are described, but were not 
encountered in our study, include  medications (anti-thyroid drugs, propylthiouracil, 
levamisole-adulterated cocaine, minocycline and hydralazine) and inflammatory bowel 
disease (IBD).[16] The high false positive rate underscores the need to increase the pre-test 
probability by limiting testing to the 1999 international consensus statement guidelines. 
 
The AAV group was predominantly renal limited vasculitis (RLV), with half these patients 
having positive ANCA serology. Elsewhere, ANCA-negative RLV has been well 
documented, highlighting the importance of tissue diagnosis as gold standard when small 
vessel vasculitis is highly suspected.[17, 18] Poorer renal outcome and less extra-renal 
involvement are seen in the ANCA negative group.[18]  
 
Limitations of this study include the retrospective folder review where clinician notes that 
may have inadequately documented the test indication, together with the large number of 
missing folders. Additionally, this audit was conducted in a tertiary hospital and results are 






Our study shows indiscriminate ANCA testing with 75.6% of tests done outside of guideline 
indications, and duplicate testing was common, with large cost implications. We also 
demonstrated false positive tests resulting in a lower PPV than described elsewhere.  
Implementing restrictive protocols for ANCA testing according to the 1999 testing 
guidelines, together with training of clinicians, is likely to reduce unnecessary tests, resulting 




Table 1:  1999 International Consensus Statement Guidelines of Indications 
for ANCA Testing*2 
Glomerulonephritis especially rapidly progressive GN 
 
Pulmonary haemorrhage especially pulmonary renal syndrome 
 
Cutaneous vasculitis with systemic features 
 
Multiple lung nodules 
 
Chronic destructive disease of the upper airways 
 
Long-standing sinusitis or otitis 
 
Subglottic tracheal stenosis 
 
















Table 2: ANCA testing according to indication guidelines per department 
 




1999 Guideline Indication Common non-guideline 
indications No 
 n=598 






4 4 (100) 0 (0) Valvular heart disease 




10 6 (60.0) 4 (40.0) Non-specific rash 
Otolaryngology 31 27 (87.1) 4 (12.9) Sensory-neural hearing 
loss, vocal cord paralysis 
Gastroenterology 
 
3 3 (100) 0 (0) IBD 
General Medicine 
 
272 173 (63.6) 99 (36.4) AKI, Stroke 
Nephrology 
 
30 15 (50.0) 15 (50.0) AKI 
Neurology 
 
100 70 (70.0) 30 (30.0) Stroke, encephalopathy 




105 83 (79.1) 22 (20.9) Uveitis, optic neuritis 
Orthopaedics 28 28 (100) 0 (0) Trigger finger, CTS, 
arthritis 
Psychiatry 2 2 (100) 0 (0) Encephalopathy, 
psychosis 
Pulmonology 35 32 (91.4) 3 (8.6) ILD, poorly controlled 
asthma, PHT 




95 94 (98.9) 1 (1.1) CLI, vascular aneurysms 
Trauma 
 
3 3 (100) 0 (0) ICA dissection, TBI 
Abbreviations: OBGYN: Obstetrics and gynaecology; AKI: Acute kidney injury; POF: premature ovarian failure; IBD: 
Inflammatory bowel disease; CTS: Carpal tunnel syndrome; ILD: Interstitial lung disease; PHT: Pulmonary hypertension; 
















Abbreviations: M: male; F: female; AAV: anti-neutrophil cytoplasmic antibody-associated vasculitis; MPO: anti-



























Gender Age Ethnicity Department AAV 
type 
MPO PR3 Guideline 
Indication 
M 55 Mixed Medicine GPA Neg Neg Yes 
F 49 Mixed  Medicine RLV Pos Neg Yes 
F 37 Mixed Medicine RLV Pos Neg Yes 
M 81 Caucasian Medicine RLV Pos Neg Yes 
F 71 Mixed Medicine RLV Pos Neg Yes 
M 39 Mixed Medicine, 
Nephrology 
RLV Neg Pos Yes 
F 58 African Medicine, 
Nephrology 
RLV Neg Neg Yes 
F 58 Mixed Nephrology RLV Neg Neg Yes 
F 29 Mixed Nephrology RLV Neg Neg Yes 
F 68 Mixed Medicine RLV Neg Neg Yes 
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Table 4: Positive anti-neutrophil cytoplasmic antibody results in patients with no 




Abbreviations: M: Male; F: Female; MPO: anti-myeloperoxidase antibodies; PR3: anti-proteinase 3 antibodies; Neg: negative; 
Pos: positive;  GN: glomerulonephritis; AKI: acute kidney injury; PN: peripheral neuropathy; ILD: interstitial lung disease; HIV: 
human immuno-deficiency virus; HIVAN: HIV associated nephropathy; TB: tuberculosis; SLE: systemic lupus erythematosus; 
LN: lupus nephritis; HPT: hypertension; AIH: autoimmune hepatitis; RA: rheumatoid arthritis; DM: diabetes mellitus; DILI: drug 











M 47 African Pos Neg Yes GN HIV, AKI due to 
hypertension 
nephrosclerosis 
F 48 African Pos Neg Yes GN HIV, HIVAN 
F 43 African Pos Neg No hepatitis HIV, confirmed DILI 
F 33 Mixed Neg Pos No Hepatomegaly and 
lymphadenopathy 
HIV, HIV seroconversion 
M 47 Mixed Neg Pos No cholangitis HIV, syphilis, confirmed 
liver abscesses 
F 44 African Pos Pos Yes Palpable purpura HIV, biopsy- cutaneous 
lupus 
M 35 African Neg Pos Yes GN TB, AKI and macroscopic 
haematuria 
F 38 African Pos neg No AKI HIV, disseminated TB 
F 30 African Pos Neg Yes PN HIV, TB 
M 39 African Pos Neg No Valve heart disease HIV, TB, epilepsy 
F 57 Mixed Neg Pos No seizures HPT, syphilis 




Pos Neg No hepatitis AIH 
F 55 African Pos Neg No Unclear SLE  
M 67 Mixed Pos Neg Yes GN HPT, biopsy- diffuse 
glomerulosclerosis 
F 69 Mixed Pos Neg Yes GN HPT, DM, asthma, 
biopsy- MCGN and ATN 
M 47 African Pos Neg No AKI - 
F 62 Mixed Pos Neg Yes PN HPT, ILD 
F 68 Mixed Pos Neg No myelopathy HPT 
F 73 Mixed Pos Neg No ILD HPT, DM 
F 54 Mixed Pos Neg No Poorly controlled 
asthma 
HPT, asthma 
M 29 African Pos Pos No uveitis - 
M 66 Mixed Neg Pos Yes scleritis HPT 
M 41 Asian Neg Pos No amblyopia - 
F 48 Mixed Neg Pos No Raynaud’s 
phenomenon 
Breast cancer in remission 
F 38 African Pos Neg No POF - 
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Fig. 1. Flow diagram of anti-neutrophil cytoplasmic antibodies performed at a tertiary 














Total ANCA tests: 
861 
728 single tests 
53 tested twice 





193 met indication 
guidelines   






Of only patients meeting 
guideline indications for 
testing:  
 14 ANCA positive 
    5 true positive 
    9 false positive 
 
179 ANCA negative 
   174 true negative 
    5 false negative 
 
Of all patients tested 
31 ANCA positive 
  5 true positive 
  26 false positive 
 
759 ANCA negative 
  754 true negative 
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consent for publication and distribution. We further recommend that the published article is 
disseminated not only to the involved researchers but also to the patients/participants from 
whom the data was drawn. Refer to Protection of Research Participants. The signed consent form 
should be submitted with the manuscript to enable verification by the editorial team. 
Other individuals 
Any individual who is identifiable in an image must provide written agreement that the 
image may be used in that context in the SAMJ. 
Copyright notice 
Copyright remains in the Author’s name. The work is licensed under a Creative Commons 
Attribution - Noncommercial Works License. Authors are required to complete and sign 
an Author Agreement form that outlines Author and Publisher rights and terms of 
publication. The Author Agreement form should be uploaded along with other 
submissions files and any submission will be considered incomplete without it. 
Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if the 
main findings of your paper have been presented at a conference and published in abstract 
form, to avoid copyright infringement. All research already published as ‘Conference 
proceedings’ needs to be substantially re-written, with a new title, a new abstract and new 
and important results to back up any study before it will be considered for a new 
publication. The SAMJ does not hold itself responsible for statements made by the authors. 
Previously published images 
If an image/figure has been previously published, permission to reproduce or alter it must 
be obtained by the authors from the original publisher and the figure legend must give full 
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credit to the original source. This credit should be accompanied by a letter indicating that 
permission to reproduce the image has been granted to the author/s. This letter should be 
uploaded as a supplementary file during submission. 
Privacy statement 
The SAMJ is committed to protecting the privacy of its website and submission system 
users. The names, personal particulars and email addresses entered in the website or 
submission system will not be made available to third parties without the user’s permission 
or due process. By registering to use the website or submission system, users consent to 
receive communication from the SAMJ or its publisher HMPG on matters relating to the 
journal or associated publications. Queries with regard to privacy may be directed to 
publishing@hmpg.co.za. 
Ethnic/race classification 
Use of racial or ethnicity classifications in research is fraught with problems. If you choose 
to use a research design that involves classification of participants based on race or 
ethnicity, or discuss issues with reference to such classifications, please ensure that you 
include a detailed rationale for doing so, ensure that the categories you describe are 
carefully defined, and that socioeconomic, cultural and lifestyle variables that may underlie 
perceived racial disparities are appropriately controlled for. Please also clearly specify 
whether race or ethnicity is classified as reported by the patient (self-identifying) or as 
perceived by the investigators. Please note that is not appropriate to use self-reported or 
investigator-assigned racial or ethnic categories for genetic studies. 
Continuing Professional Development (CPD) 
SAMJ is an HPCSA-accredited service provider of CPD materials. Principal authors can earn 
up to 15 CPD continuing education units (CEUs) for publishing an article; co-authors are 
eligible to earn up to 5 CEUs; and reviewers of articles can earn 3 CEUs. Each 
month, SAMJ also publishes a CPD-accredited questionnaire relating to the academic 
content of the journal. Successful completion of the questionnaire with a pass rate of 70% 
will earn the reader 3 CEUs. Administration of our CPD programme is managed by Medical 
Practice Consulting. To complete questionnaires and obtain certificates, please visit MRP 
Consulting 
Manuscript preparation 
Preparing an article for anonymous review 
To ensure a fair and unbiased review process, all submissions are to include an anonymised 
version of the manuscript. The exceptions to this are Correspondence, Book reviews and 
Obituary submissions. 
Submitting a manuscript that needs additional blinding can slow down your review process, 
so please be sure to follow these simple guidelines as much as possible: 
• An anonymous version should not contain any author, affiliation or particular institutional
details that will enable identification.
• Please remove title page, acknowledgements, contact details, funding grants to a named
person, and any running headers of author names.




General article format/layout 
Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, which will delay publication. 
  
General: 
• Manuscripts must be written in UK English. 
• The manuscript must be in Microsoft Word format. Text must be single-spaced, in 12-point 
Times New Roman font, and contain no unnecessary formatting (such as text in boxes). 
• Please make your article concise, even if it is below the word limit. 
• Qualifications, full affiliation (department, school/faculty, institution, city, country) and 
contact details of ALL authors must be provided in the manuscript and in the online 
submission process. 
• Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
• Include sections on Acknowledgements, Conflict of Interest, Author Contributions and 
Funding sources. If none is applicable, please state ‘none’.  
• Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dL). 
• Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
• Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' but 
'50%' and '19ºC'. 
• Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not B for 
beta, etc. 
• Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
• Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
• If you wish material to be in a box, simply indicate this in the text. You may use the table 
format –this is the only exception. Please DO NOT use fill, format lines and so on. 
  
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, 
although they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ 
can be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
• Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
• HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
• OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
• Bennet et al. Standardized human pedigree nomenclature: Update and assessment of the 
recommendations of the National Society of Genetic Counselors. J Genet Counsel 
2008;17:424-433: standard human pedigree nomenclature. 





• In Practice and Case reports 
• Reviews 
• Clinical trials 
• Correspondence 
• Obituaries 




Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that 
clearly lay out the rationale for conducting the study. Some common reasons for conducting 
a study are: to fill a gap in the literature, a logical extension of previous work, or to answer 
an important clinical question. If other papers related to the same study have been 
published previously, please make sure to refer to them specifically. Describe the study 
methods in as much detail as possible so that others would be able to replicate the study 
should they need to. Results should describe the study sample as well as the findings from 
the study itself, but all interpretation of findings must be kept in the discussion section, 
which should consider primary outcomes first before any secondary or tertiary findings or 
post-hoc analyses. The conclusion should briefly summarise the main message of the paper 
and provide recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text . 
  
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the intervention, 
primary and secondary outcomes, any specific analyses that were done on the data. 
o Results: first sentence must be brief population and sample description; outline the results 
according to the methods described. Primary outcomes must be described first, even if they 
are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
• Do not include any references in the abstracts. 
  
  




All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
• Objectives (within Introduction/Background): a clear statement of the main aim of the study 
and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural factors 
(e.g. smoking status, socioeconomic group, educational attainment, co-existing disease 
indicators, etc)that may have an impact on the study results. Clearly define how participants 
were enrolled, and describe selection and exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long. Typically for randomised 
controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and those 
ultimately measured. Explain differences, if any. 
  
Results 
• Start with description of the population and sample. Include key characteristics of comparison 
groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, 
the exact level of statistical significance and the number need to treat/harm. Whenever 
possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house style is to present 
this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean 
(SD). 
• Leave interpretation to the Discussion section. The Results section should just report the 
findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and policymakers 
• Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 
not go beyond the data in the article. 
  
Editorials 
Guideline word limit: 1 000 words 
55 
These opinion or comment articles are usually commissioned but we are happy to consider 
and peer review unsolicited editorials. Editorials should be accessible and interesting to 
readers without specialist knowledge of the subject under discussion and should have an 
element of topicality (why is a comment on this issue relevant now?) There should be a 
clear message to the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
• expert opinion




CME (by invite only) 
CME is intended to provide readers with practical, up-to-date information on medical and 
related matters. It is aimed at those who are not specialists in the field. 
From January 2016, all CME articles will be printed in full in the SAMJ. Please try to adhere 
strictly to the guidelines on word count as we have a page limit for the print issue of 
the SAMJ. We reserve the right to place some tables and reference lists online if this is 
necessary for space. 
In practice, this means that each CME topic usually covers two issues of the print issue of 
the SAMJ. 
The guest editor, in consultation with the editor, is responsible for convening a team of 
authors, deciding on the subjects to be covered and for reviewing the manuscripts 
submitted. The suggestion is for 4 - 5 articles, although there is some room for flexibility 
contingent on discussions with the editor. 
For queries about these guidelines please feel free to contact the CME editor, Dr Bridget 
Farham, by email (ugqirha@iafrica.com) or telephone (+27 (0)82 452 2860) 
Review process 
The guest editor reviews the articles and returns them to the CME editor for review and final 
approval. 
Guest editorials 
Guideline word limit: 1 000 words 
• Include the guest editor’s personal details (qualifications, positions, affiliation, e-mail
address, and a short personal profile (50words)).
• If possible, include a photograph of the author(s) at high enough resolution for print. It is
preferable to provide two guest editorials, one for each issue, so that the content of the
articles in each issue is covered.
Articles 
Guideline word limit: 2 000 - 3 000 words 
• Each article requires an abstract of ±200 words.
• The editor reserves the right to shorten articles but will send a substantially shortened article
back for author approval.
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Personal details 
Please supply: Your qualifications, position and affiliations and MP number (used for CPD 
points); Address, telephone number and fax number, and your e-mail address; and a short 
personal profile (50words)and a few words about your current fields of interest. 
In Practice 
Guideline word limit: 2 000 - 3 000words 
This section includes articles that would previously have been accepted into the Forum 
section, and case reports. 
In practice articles are those that draw attention to specific issues of clinical, economic or 





• Issues in medicine
• Issues in public health
• Healthcare delivery
• Medicine and the environment
• Medicine and the law
• Cochrane corner
An In Practice article should follow the following format – sub-headings are not necessary, 
but may be used for clarity: 
• Author affiliations and qualifications: to be the same as for Research. Provide all authors’
names and initials, qualifications and full affiliations, and corresponding author.
• Short abstract: does not need to be structured, but should capture the essential features of
the article
• Introduction: the reason for the article and the issue being addressed
• Recent research, discussion, local policy around the issue – include your own research where
appropriate
• All statements should be referenced and, if opinion only, this should be stated
• Discussion: how this article adds to the discussion around a particular topic
• If a clinical practice or policy point is at issue, this needs to be emphasised, using a box with
highlights if appropriate.
Essentially In practice is an opportunity for a more discursive approach to topics of clinical, 
economic or political importance in southern African health systems. It is not an opportunity 
to put forward unsubstantiated opinions! 
Case reports 
The SAMJ has recently started to accept case reports. The cases must come from Africa, 
preferably southern Africa unless the condition is common to all African countries, and must 
be either a completely new description of a clinical condition or result (use Google!) or a 
case that highlights important practice or management issues. 
Please use the following format for case reports: 
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• Title of case: do not include the words ‘a case report’ in the title
• Summary/abstract:  up to 150 words summarising the case presentation and outcome
• Background: why is this case important and why did you write it up?
• Case presentation: presenting features, medical, social, family history as appropriate
• Case management: should be according to best practice, and if not, please explain why
• Investigations, if relevant: save space by simply saying ‘normal’ if, for example, renal
function was completely normal, rather than listing normal results, highlight the abnormal –
or indeed the normal if this is clinically significant
• Differential diagnosis, if relevant
• Treatment, if relevant
• Outcome and follow-up
• Discussion – a VERY BRIEF review of similar published cases
• Teaching points: 3 - 5 bullet points
• References: as per the SAMJ house style
• Tables and figures: keep to a minimum. Use clinical images where relevant – we need hi-res
versions for print, and identifiable persons must have a consent form
• Patient consent: please include a statement about patient consent to a written case report.
This should be uploaded as a supplementary file.
Clinical trials 
Guideline word limit: 4000 words 
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should be 
registered with the appropriate national clinical trial registry (or any international primary 
register, if relevant), and the trial registration number should be cited at the end of the 
abstract. Since 1st December 2005, all clinical trials conducted in South Africa have been 
required to be registered in the South African National Clinical Trials Register. The SAMJtherefore 
requires that clinical trials be registered in the relevant public trials registry at or before the 
time of first patient enrollment as a condition for publication. The trial registry name and 
registration number must be included in the manuscript. 
Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format 
of original research articles should be followed for reporting of clinical trial results. 
Review articles 
Guideline word limit: 4 000 words 
These are welcome, but should be either commissioned or discussed with the Editor before 
submission. A review article should provide a clear, up-to-date account of the topic and be 
aimed at non-specialist hospital doctors and general practitioners. 
Please ensure that your article includes: 
• Abstract: unstructured, of about 100-150 words, explaining the review and why it is
important
• Methods: Outline the sources and selection methods, including search strategy and keywords
used for identifying references from online bibliographic databases. Discuss the quality of
evidence.
• When writing: clarify the evidence you used for key statements and the strength of the
evidence. Do not present statements or opinions without such evidence, or if you have to,
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say that there is little or no evidence and that this is opinion. Avoid specialist jargon and 
abbreviations, and provide advice specific to southern Africa. 
• Personal details: Please supply your qualifications, position and affiliations and MP number 
(used for CPD points); address, telephone number and fax number, and your e-mail address; 
and a short personal profile (50 words) and a few words about your current fields of interest. 
  
Correspondence (Letters to the Editor) 
Guideline word limit: 500 words 
  
Letters to the editor should relate either to a paper or article published by the SAMJ or to a 
topical issue of particular relevance to the journal’s readership 
  
• May include only one illustration or table 
• Must include a correspondence address. 
  
Book reviews 
Guideline word limit: 400 words 
Should be about 400 words and must be accompanied by the publication details of the book. 
Provide a hi-res image of the cover if possible (with permission from the copyright holder). 
  
Obituaries 
Guideline word limit: 400 words 
Should be offered within the first year of the practitioner’s death, and may be accompanied 
by a photograph. 
  
Guidelines  
Guidelines should always be discussed with the Editor prior to submission. 
  
Because of the intensive review process required to ensure Guidelines are independent, 
evidence-based and free from commercial bias, they are usually published as a supplement 
to the SAMJ, the costs of which must be covered by sponsorship, advertising or payment by 
the guideline authors/association. We will provide a quote based on the expected length of 
the guideline and whether it is to appear online only, or in print, which must be accepted by 
the body putting the guidelines together before submitting the work to the SAMJ. 
  
The Editor reserves the right to determine the scheduling of supplements. Understandably, 
a delay in publication must be anticipated dependent upon editorial workflow. 
All guidelines should include a clear, transparent statement about all sources of funding and 
an explicit, clear statement of conflicts of interest of any of the participants in the guidelines 
about industry funding for lectures, research, conference participation etc.  
All guidelines should be structured according to Agree II. 
Please access this website before putting the guidelines together, download the Agree 11 
instrument and use this to put the guidelines together. 
All submitted guidelines will be sent to the local Agree II appraisal committee for review and 
must be endorsed by an appropriate body prior to consideration and all conflicts of interest 
expressed. 
  
A structured abstract not exceeding 400 words (recommended sub-headings: Background, 
Recommendations, Conclusion) is required. Sections and sub-sections must be numbered 
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consecutively (e.g. 1. Introduction; 1.1 Definitions; 2.etc.) and summarised in a Table of 
Contents. 
Illustrations/photos/scans 
• If illustrations submitted have been published elsewhere, the author(s) should provide
consent to republication obtained from the copyright holder.
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'.
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full).
• All images must be of high enough resolution/quality for print.
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form.
• Ensure all graph axes are labelled appropriately, with a heading/description and units (as
necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0
etc.
• Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of a low
malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow to show
the tumour.
• Each image must be attached individually as a 'supplementary file' upon submission (not
solely embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc.
Tables 
• Tables should be constructed carefully and simply for intelligible data representation.
Unnecessarily complicated tables are strongly discouraged.
• Large tables will generally not be accepted for publication in their entirety. Please consider
shortening and using the text to highlight specific important sections, or offer a large table as
an addendum to the publication, but available in full on request from the author
• Embed/include each table in the manuscript Word file - do not provide separately as
supplementary files.
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively in
the text.
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable.
• Ensure each table has a concise title and column headings, and include units where
necessary.
• Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || then
** †† ‡‡ etc.
Do not: Use [Enter] within a row to make ‘new rows’: 
Rather: 
Each row of data must have its own proper row: 
Do not: use separate columns for n and %: 
Rather: 
Combine into one column, n (%): 
Do not: have overlapping categories, e.g.: 
Rather: 
Use <> symbols or numbers that don’t overlap: 
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References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
• Authors must verify references from original sources.
• Citations should be inserted in the text as superscript numbers between square brackets, e.g.
These regulations are endorsed by the World Health Organization,[2] and others.[3,4-6]
• All references should be listed at the end of the article in numerical order of appearance in
the Vancouver style (not alphabetical order).
• Approved abbreviations of journal titles must be used; see the List of Journals in Index Medicus.
• Names and initials of all authors should be given; if there are more than six authors, the first
three names should be given followed by et al.
• Volume and issue numbers should be given.
• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17.
• Wherever possible, references must be accompanied by a digital object identifier (DOI) link).
Authors are encouraged to use the DOI lookup service offered by CrossRef:
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box.
o Look for the correct, matching article in the list of results.
o Click Actions > Cite
o Alongside 'url =' copy the URL between { }.
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x
Some examples: 
• Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about
glaucoma. Stat Med 1998;289(1):350-355. http://dx.doi.org/10.1000/hgjr.182
• Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth,
1975:96-101.
• Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading
Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic Physiology: Mechanisms of
Disease. Philadelphia: WB Saunders, 1974:457-472.
• Internet references: World Health Organization. The World Health Report 2002 - Reducing




National Department of Health, South Africa. National Policy for Health Act, 1990 (Act No. 
116 of 1990). Free primary health care services. Government Gazette No. 17507:1514. 
1996. 
In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the notice 
number in this Gazette. 
• Provincial Gazettes:
Gauteng Province, South Africa; Department of Agriculture, Conservation, Environment and 
Land Affairs. Publication of the Gauteng health care waste management draft regulations. 
Gauteng Provincial Gazette No. 373:3003, 2003. 
• Acts:
South Africa. National Health Act No. 61 of 2003. 
• Regulations to an Act:
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South Africa. National Health Act of 2003. Regulations: Rendering of clinical forensic 
medicine services. Government Gazette No. 35099, 2012. (Published under Government 
Notice R176). 
•              Bills: 
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006. 
•              Green/white papers: 
South Africa. Department of Health Green Paper: National Health Insurance in South Africa. 
2011. 
•              Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another:  Name of the parties concerned 
1949: Date of decision (or when the case was heard) 
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) woud indicate Cape, (G) 
Gauteng, and so on. 
NOTE: no . after the v 
• Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher 
place: Publisher name, year; pages. 
• Cited manuscripts that have been accepted but not yet published can be included as 
references followed by '(in press)'. 
• Unpublished observations and personal communications in the text must not appear in the 
reference list. The full name of the source person must be provided for personal 
communications e.g. '...(Prof. Michael Jones, personal communication)'. 
  
From submission to acceptance 
Submission and peer-review 
To submit an article: 
• Please ensure that you have prepared your manuscript in line with the SAMJ requirements. 
• All submissions should be submitted via Editorial Manager 
• The following are required for your submission to be complete: 
o Anonymous manuscript (unless otherwise stated) 
o Manuscript 
o Any supplementary files: figures, datasets, patient consent form, permissions for published 
images, etc. 
• Once the submission has been successfully processed on Editorial Manager, it will undergo a 
technical check by the Editorial Office before it will be assigned to an editor who will handle 
the review process. If the author guidelines have not been appropriately followed, the 






Please note that there is a 6-month waiting time for publication, once an article has been 
sent to the production team. 
The following process will follow: 
1. An accepted manuscript is passed to a Managing Editor to assign to a copyeditor (CE).
2. The CE copyedits in Word, working on house style, format,
spelling/grammar/punctuation, sense and consistency, and preparation for
typesetting.
3. If the CE has an author queries, he/she will contact the corresponding author and
send them the copyedited Word doc, asking them to solve the queries by means of
track changes or comment boxes.
4. The authors are typically asked to respond within 1-3 days. Any comments/changes
must be clearly indicated e.g. by means of track changes. Do not work in the original
manuscript - work in the copyedited file sent to you and make your changes clear.
5. The CE will finalise the article and then it will be typeset.
6. Once typeset, the CE will send a PDF of the file to the authors to complete their final
check, while simultaneously sending to the 2nd-eye proofreader.
7. The authors are typically asked to complete their final check and sign-off within 1-2
days. No major additional changes can be accommodated at this point.
8. The CE implements the authors’ and proofreader’s mark-ups, finalises the file, and
prepares it for the upcoming issue.
Changing contact details or authorship 




Online v. print 
The SAMJ is an online journal. The online version of the journal is the one that has the 
widest circulation, is indexed by bibliographic databases including PubMed and SciELO, and 
is accessible in academic libraries. A printed edition , containing material selected by the 
Editor is also published each month and distributed to the membership of the South African 
Medical Association. 
Online 
• The full text of all accepted articles is published in full online, open access.
• Citation information of each article is based on its online publication.
• You may want to make use of the advantages of online publication e.g. specify web links to
other sources, images, data or even a short video.
Print 
• Not all articles will be selected for print.
• An article may be selected for print in a different month from that in which it was published
online.
• Research articles will appear in abstract form only, if selected for a print edition.
Errata and retractions 
Errata 
Should you become aware of an error or inaccuracy in yours or someone else’s contribution 
after it has been published, please inform us as soon as possible via an email to 
publishing@hmpg.co.za,including the following details: 
• Journal, volume and issue in which published
• Article title and authors
• Description of error and details of where it appears in the published article
• Full detail of proposed correction and rationale
We will investigate the issue and provide feedback. If appropriate, we will correct the web 
version immediately, and will publish anerratum  in the next issue. The correction will be 
indexed, as PubMed has a function for linking errata back to the original article. All 
investigations will be conducted in accordance with guidelines provided by the Committee on 
Publication Ethics (COPE). 
Retractions 
Retraction of an article is the prerogative of either the original authors or the editorial team 
of HMPG. Should you wish to withdraw your article before publication, we need a signed 
statement from all the authors. 
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Should you wish to retract your published article, all authors have to agree in writing before 
publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
• Journal, volume and issue to which article was submitted/in which article was published
• Article title and authors
• Description of reason for withdrawal/retraction.
We will make a decision on a case-by-case basis upon review by the editorial committee in 
line with international best practices. Comprehensive feedback will be communicated with 
the authors with regard to the process. In case where there is any suspected fraud or 
professional misconduct, we will follow due process as recommended by the Committee on 
Publication Ethics (COPE), and in liaison with any relevant institutions. 
When a retraction is published, it will be linked to the original article. 
Indexing 
The SAMJ has an impact factor of 1.5. 
Published articles are covered by the following major indexing services. As such articles 
published in the SAMJ are immediately available to all users of these databases, guaranteed 
a global and African audience: 
• Index Medicus (Medline/PubMed)
• ExcerptaMedica (EMBASE)
• Biological Abstracts (BIOSIS)
• Science Citation Index (SciSearch)








Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
Copyright Notice 
Copyright of published material remains in the Authors’ name. This allows authors to use 
their work for their own non-commercial purposes without seeking permission from the 
Publisher, subject to properly acknowledging the Journal as the original place of publication. 
 Authors are free to copy, print and distribute their articles, in full or in part, for teaching 
activities, and to deposit or include their work in their own personal or institutional database 
or on-line website. Authors are requested to inform the Journal/Publishers of their 
desire/intention to include their work in a thesis or dissertation or to republish their work in 
any derivative form (but not for commercial use).  
 Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if the 
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main findings of your paper have been presented at a conference and published in abstract 
form, to avoid copyright infringement. 
Privacy Statement 
The SAMJ is committed to protecting the privacy of the users of this journal website. The 
names, personal particulars and email addresses entered in this website will be used only 
for the stated purposes of this journal and will not be made available to third parties without 
the user’s permission or due process. Users consent to receive communication from 
the SAMJ for the stated purposes of the journal. Queries with regard to privacy may be 
directed to publishing@hmpg.co.za. 
